Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2015

01-12-2015 | Editorial

The association between methylenetetrahydrofolate reductase gene C677T polymorphisms and breast cancer risk in Chinese population

Authors: Yadong Wang, Haiyan Yang, Huiyan Gao, Haiyu Wang

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

With great interest, we read the recent article entitled “Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk in Chinese population: a meta-analysis of 22 case-control studies” published online in Tumor Biology, 2014, 35: 1695–1701. This article suggests that methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism was significantly associated with breast cancer risk in Chinese population. The result is encouraging. Nevertheless, three key issues in this meta-analysis are worth noticing.
Literature
1.
Liang H, Yan Y, Li T, Li R, Li M, Li S, et al. Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk in Chinese population: a meta-analysis of 22 case-control studies. Tumour Biol. 2014;35:1695–701.CrossRefPubMed
2.
Lin WY, Chou YC, Wu MH, Huang HB, Jeng YL, Wu CC, et al. The MTHFR C677T polymorphism, estrogen exposure and breast cancer risk: a nested case-control study in Taiwan. Anticancer Res. 2004;24:3863–8.PubMed
3.
Han H, Han L, Gao H, Hou L. Genetic polymorphisms of methylenetetrahydrofolate reductase, methionine synthase, methylation of NF2, and their association with breast cancer morbidity. Chin J Curr Adv Gen Surg. 2011;14:846–50.
4.
Wu Y, Wu L, Wang Y, Cao W, Hou L. Relation between the SNPs in methylenetetrahydrofolate reductase gene C677T and G1793A and the susceptibility of sporadic breast cancer. Prog Mod Biomed. 2012;12:2609–14.
5.
Gao CM, Tang JH, Cao HX, Ding JH, Wu JZ, Wang J, et al. MTHFR polymorphisms, dietary folate intake and breast cancer risk in Chinese women. J Hum Genet. 2009;54:414–8.CrossRefPubMed
6.
Cheng CW, Yu JC, Huang CS, Shieh JC, Fu YP, Wang HW, et al. Polymorphism of cytosolic serine hydroxymethyltransferase, estrogen and breast cancer risk among Chinese women in Taiwan. Breast Cancer Res Treat. 2008;111:145–55.CrossRefPubMed
7.
He JM, Pu YD, Wu YJ, Qin R, Zhang QJ, Sun YS, et al. Association between dietary intake of folate and MTHFR and MTR genotype with risk of breast cancer. Genet Mol Res. 2014;13:8925–31.CrossRefPubMed
8.
Hua Z, Wang Y, Ni J, Ge F, Zou T. Folic acid, vitamin B12, MTHFR, MS gene polymorphisms associate with the risk of breast cancer. Mod Oncol. 2011;19:428–31.
9.
Huang CY, Chang WS, Shui HA, Hsieh YH, Loh CH, Wang HC, et al. Evaluation of the contribution of methylenetetrahydrofolate reductase genotypes to Taiwan breast cancer. Anticancer Res. 2014;34:4109–15.PubMed
10.
Inoue M, Robien K, Wang R, Van Den Berg DJ, Koh WP, Yu MC. Green tea intake, MTHFR/TYMS genotype and breast cancer risk: the Singapore Chinese Health Study. Carcinogenesis. 2008;29:1967–72.CrossRefPubMedPubMedCentral
11.
Kan X, Zou T, Wu X, Wang X. Association between MTHFR genotype polymorphism and breast cancer susceptibility in human population from Yunnan. Cancer Res Prev Treat. 2007;34:716–8.
12.
Li W, Chen S. MTHFR C677T gene polymorphism associated with breast cancer. Pract J Med. 2009;25:2031–3.
13.
Liu Y, Zhou LS, Xu XM, Deng LQ, Xiao QK. Association of dietary intake of folate, vitamin B6 and B12 and MTHFR genotype with breast cancer risk. Asian Pac J Cancer Prev. 2013;14:5189–92.CrossRefPubMed
14.
Qi J, Miao XP, Tan W, Yu CY, Liang G, Lu WF, et al. Association between genetic polymorphisms in methylenetetrahydrofolate reductase and risk of breast cancer. Zhonghua Zhong Liu Za Zhi. 2004;26:287–9.PubMed
15.
Qiao J, Jiao D, Lu Z, Cui S, Liu Z. Association of methylenetetrahydrofolate reductase and methionine synthase polymorphisms with breast cancer risk and interaction with folate, vitamin B6, and vitamin B12 intakes. Tumor Biol. 2014;35:11895–901.CrossRef
16.
Shrubsole MJ, Gao YT, Cai Q, Shu XO, Dai Q, Hebert JR, et al. MTHFR polymorphisms, dietary folate intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev. 2004;13:190–6.CrossRefPubMed
17.
Wu XY, Ni J, Xu WJ, Zhou T, Wang X. Interactions between MTHFR C677T-A1298C variants and folic acid deficiency affect breast cancer risk in a Chinese population. Asian Pac J Cancer Prev. 2012;13:2199–206.CrossRefPubMed
18.
Xi J, Su Y, Fadiel A, Lin Y, Su F, Jia W, et al. Association of physical activity and polymorphisms in FGFR2 and DNA methylation related genes with breast cancer risk. Cancer Epidemiol. 2014;38:708–14.CrossRefPubMed
19.
Yu CP, Wu MH, Chou YC, Yang T, You SL, Chen CJ, et al. Breast cancer risk associated with multigenotypic polymorphisms in folate-metabolizing genes: a nested case-control study in Taiwan. Anticancer Res. 2007;27:1727–32.PubMed
20.
Yuan H, Xu X, Wang Z. The relation between polymorphism of methylenetetrahydrofolate reductase C677T and the risk of breast cancer. J Mudanjiang Med Univ. 2009;30:2–4.
Metadata
Title
The association between methylenetetrahydrofolate reductase gene C677T polymorphisms and breast cancer risk in Chinese population
Authors
Yadong Wang
Haiyan Yang
Huiyan Gao
Haiyu Wang
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3321-6

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue

Original Article

TLR2∆22 (-196-174) significantly increases the risk of breast cancer in females carrying proline allele at codon 72 of TP53 gene: a case–control study from four ethnic groups of North Eastern region of India

Research Article

RETRACTED ARTICLE: Interaction between TNFR1 and TNFR2 dominates the clinicopathologic features of human hypopharyneal carcinoma

Research Article

Speckle-type POZ protein is negatively associated with malignancies and inhibits cell proliferation and migration in liver cancer

Research Article

Glucose-regulated protein 94 is a novel glioma biomarker and promotes the aggressiveness of glioma via Wnt/β-catenin signaling pathway

Research Article

BMP-2 induces motility and invasiveness by promoting colon cancer stemness through STAT3 activation

Original Article

Prolonged and repetitive exposure to Porphyromonas gingivalis increases aggressiveness of oral cancer cells by promoting acquisition of cancer stem cell properties
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits